GEN Exclusives

More »

GEN News Highlights

More »
Jun 24, 2010

Crucell and J&J to Develop RSV Vaccine

  • Crucell will commence a discovery program for a universal respiratory syncytial virus (RSV) vaccine. The vaccine will be designed to prevent severe infections with the most common RSV strains in infants and the elderly. This discovery program is part of an existing strategic collaboration with Johnson & Johnson through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals.

    In September 2009, Johnson & Johnson and Crucell entered into a strategic collaboration for the development and commercialization of a universal monoclonal antibody product for the treatment and prevention of influenza A. The collaboration involves four programs focused on the development and commercialization of a universal influenza A vaccine as well as innovative products directed against three other disease targets. The universal RSV vaccine was selected as the second program.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?